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Routine dexamethasone therapy for bacterial meningitis in pediatric patients is controversial.
Two experts debated this topic at the 1993 meeting of the Infectious Diseases Society of Amer-
ica. Both experts agreed that for management of Haemophilus influenzae meningitis, dexametha-
sone significantly reduced sensorineural hearing loss and probably reduced other long-term se-
quelae. Because relatively few patients with pneumococcal and meningococcal meningitis have
been studied, no conclusions could be reached regarding the effectiveness of dexamethasone. Dr.
Urs Schaad emphasized the impressive anti-inflammatory effects of dexamethasone in experi-
mental pneumococcal meningitis and the lack of any adverse events when given to children for 2
or 4 days. He recommended routine use of dexamethasone in treating pediatric patients with
bacterial meningitis. Dr. Sheldon Kaplan expressed concern regarding the effectiveness of ste-
roids in treating pneumococcal meningitis, especially when penicillin-resistant and cephalospo-
rin-resistant isolates are present, and he addressed the question of the long-term effects of admin-
istration of dexamethasone in children with viral meningitis. He advised against the routine use
of dexamethasone for non–H. influenzae meningitis.
At the annual meeting of the Infectious Diseases Society
of America in October 1993, one of the sessions was devoted
to the controversy of whether dexamethasone should be rou-
tinely used to treat patients with bacterial meningitis. The
two physicians chosen to address this issue had recently con-
ducted multicenter, placebo-controlled, double-blind stud-
ies of dexamethasone therapy in children with meningitis.
Dr. Urs B. Schaad was asked to present information support-
ing the routine use of dexamethasone therapy in these pa-
tients. Dr. Sheldon L. Kaplan took the opposing view—that
dexamethasone should be used only in select patients with
bacterial meningitis. The following paper represents a distil-
lation of their presentations and a commentary by Dr.
George H. McCracken, Jr.
Affirmative View
Bacterial meningitis remains an important cause of death
and permanent neurological disability despite advances in
antimicrobial therapy, rapid diagnostic techniques, and sup-
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portive care. The two main strategies for further reducing the
impact of purulent meningitis are prevention of disease by
active immunization against the common bacterial patho-
gens and reduction of CNS pathology by use of appropriate
antiinflammatory measures.
Data from recent in vitro and animal experiments indicate
that the bacteria causing meningitis elaborate outer mem-
brane–active or cell wall–active components that affect
monocytes, leukocytes, cerebrovascular endothelial cells,
and astrocytes [1-3]. These cells, in turn, produce various
proinflammatory cytokines or express specific receptors on
their surface. These cytokines and receptors initiate an accel-
erating cascade of events, resulting in alteration of the blood-
brain barrier, meningeal inflammation, increased intracra-
nial pressure, and decreased cerebral vascular perfusion. If
the interaction of these pathopysiological alterations is se-
vere and sustained, it will produce neuronal injury and irre-
versible focal or diffuse brain damage.
Dexamethasone is a potent antiinflammatory agent. There
is convincing in vitro and in vivo evidence that this steroid
decreases the liberation of various cytokines [4-6]. Other ef-
fects of dexamethasone, some of which may be independent
of its effect on cytokine release, include reduction of brain
edema, intracranial pressure, blood-brain barrier permeabil-
ity, and CSF lactate concentrations. These findings suggest a
beneficial effect of this drug in the treatment of bacterial
meningitis, especially when given before the first dose of anti-
biotics.
Five recent clinical studies have evaluated the use of dexa-
methasone as part of the initial regimen for management of
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bacterial meningitis [7-10]. All of these studies showed a
reduction in neurological sequelae when patients were given
dexamethasone therapy. Because of the relatively small num-
bers of patients enrolled in the therapeutic arms of these
clinical trials, beneficial effects were statistically significant
only when sequelae were unusually common because of sub-
optimal antibiotic treatment (i.e., cefuroxime) or because of
suboptimal supportive and diagnostic management (i.e., the
studies were conducted in developing countries). For these
reasons, routine use of steroid therapy for bacterial meningi-
tis remains controversial for some physicians and repre-
sented a good topic for discussion at this meeting.
To assess the effects of dexamethasone therapy on the
course and outcome of bacterial meningitis in Swiss children,
we conducted a prospective, placebo-controlled, double-
blind, multicenter study of children who received ceftriax-
one and routine supportive treatment for meningitis [11].
On the basis of pathophysiological and pharmacokinetic
data [1, 2, 12], and for achievement of maximum benefits
and minimum complications, dexamethasone therapy was
started 10 minutes before the first dose of ceftriaxone was
administered, and it was given every 12 hours for only 2
days. Results from animal studies strongly indicate that the
optimal time for adjunctive dexamethasone therapy is just
before administration of the first dose of parenteral antibi-
otics [4-6]. Exacerbation of inflammation that occurred dur-
ing the initial antibiotic therapy in pediatric patients with
Haemophilus influenzae meningitis was shown by documenta-
tion of a substantial increase in cytokine concentrations in
the CSF 2-6 hours after the first dose of ceftriaxone was
administered [13].
All 115 pediatric study patients with acute bacterial menin-
gitis received ceftriaxone (100 mg/kg body weight) in one
single daily intravenous dose. By random assignment, 55 pa-
tients received placebo and 60 patients received four intrave-
nous doses of dexamethasone (.4 mg/kg body weight) over 2
days; the first dose of dexamethasone was given 10 minutes
before the first ceftriaxone dose was given, and the next three
doses were given every 12 hours. Baseline demographic, clin-
ical, and laboratory features of the two groups were similar.
After 24 hours of treatment, meningeal inflammation (as
shown by CSF glucose concentration) was significantly in-
creased in those given dexamethasone compared with those
given placebo (mean percentage increase in glucose concen-
tration, 63 mg/dL vs. 40 mg/dL; P = .008). However, at 24
hours of therapy, other indices of inflammation showed that
changes were similar in both groups.
Addition of dexamethasone did not affect the rate at
which CSF became sterile. Both groups showed prompt clini-
cal responses and similar frequencies of acute complications:
12% for the dexamethasone group vs. 15% for the placebo
group. Fever resolved more rapidly in patients receiving dexa-
methasone, but they experienced secondary fever more fre-
quently. However, the probable causes of secondary fever
did not include any complication of bacterial infection. An
antipyretic action of dexamethasone that is followed by a
rebound effect has been previously observed [7].
We monitored for possible adverse effects of dexametha-
sone and saw no abnormalities. Despite more frequent detec-
tion of occult blood in the stool of those patients treated with
dexamethasone, there was neither overt gastrointestinal
bleeding nor a substantial drop in the blood hemoglobin
concentration in any of the study patients.
At follow-up examinations 3, 9, and 15 months after dis-
charge from the hospital, 3 (5%) of 60 dexamethasone recipi-
ents and 9 (16%) of 55 placebo recipients had one or more
neurological or audiological sequelae (P = .066); the relative
risk of sequelae in placebo recipients was 3.27 (95% CI: .93—
11.47).
The study designs of two other prospective, double-blind
trials ofadjunctive dexamethasone therapy for bacterial men-
ingitis [7, 14, 15] were similar to that of our study (11); all
children received ceftriaxone, and the diagnostic and sup-
portive management of the patients in the two other studies
was similar to that in ours. The results of a meta-analysis
(table 1) of these three studies to determine the risk of devel-
oping any sequelae showed that the relative risk of develop-
ing persistent neurological and/or audiological sequelae for
children treated with placebo was 2.29 (95% CI: 1.20-4.39).
Because only 60 (17%) of 352 patients enrolled in these
three studies [7, 11, 15] had meningitis caused by Streptococ-
cus pneumoniae, it was not possible to determine conclu-
sively whether dexamethasone was as effective when used to
treat infants and children with pneumococcal meningitis.
We compared the data from these three studies with the re-
sults of a retrospective analysis of pediatric patients with
pneumococcal meningitis treated in Dallas from 1984 to
1990 [16]. In the first three studies, adverse neurological or
audiological sequelae were documented in 9 (26%) of 34 pa-
tients receiving placebo as compared with 14 (33%) of 43
non-steroid-treated and 3 (9%) of 32 dexamethasone-treated
patients (P = .025) in the retrospective analysis. These clini-
cal data are also consistent with results from a model for
experimental pneumococcal meningitis [1-3, 5]. We need
additional data on dexamethasone therapy used in conjunc-
tion with other classes of antibiotics (such as vancomycin
and rifampin) to determine its effect in patients with meningi-
tis due to penicillin-resistant and cephalosporin-resistant
pneumococci.
Factors other than antibacterial and anti-inflammatory
therapies can affect the outcome for patients with meningitis;
for example, type and virulence of the causative etiologic
agent (especially S. pneuinoniae), initial severity of disease,
time to sterilization of CSF, and the rate of complications
during hospital stay all affect outcome. Our results except for
delayed sterilization of CSF confirmed these relationships.
Knowledge of these prognostic factors is essential for ade-
quate management of patients with bacterial meningitis, but
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Table 1. Meta-analysis of persistent sequelae reported in three studies of children treated for bacte-
rial meningitis with ceftriaxone plus dexamethasone or placebo.
Study location
[reference]
No. of patients with any neurological
or audiological sequelae
P value*
Relative risk
(95% CI)tPlacebo Dexamethasone
Dallas [7, 14] 9/46 (20) 3/49 (6) .065 3.20
(0.92-11.08)
United States [15] 10/74 (14) 6/68 (9) .434 1.53
(0.59-3.99)
Switzerland [11] 9/55 (16) 3/60 (5) .066 3.27
(0.93-1 1.47)
Total* 28/175 (16) 12/177 (7) NA 2.29
(1.20-4.39)
NOTE. CI = confidence interval; NA = not applicable.
* Significance is based on the comparison of the two treatment groups.
t The relative risks presented are for a patient in the placebo group as compared with a patient in the dexametha-
sone group.
Results of all three studies combined.
does not help in the determination of initial antimicrobial
and anti-inflammatory therapy, which needs to be started as
soon as a diagnosis of meningitis is suspected. The results of
our study and of the meta-analysis convince me that adjunc-
tive dexamethasone therapy improves the outcome for in-
fants and children with bacterial meningitis. Thus, I recom-
mend the use of adjunctive dexamethasone therapy in these
patients, preferably at the dose regimen used in our study.
Final recommendations regarding the use of dexamatho-
sone in the treatment of bacterial meningitis in neonatal and
adult patients can not be made until the results of ongoing
studies are known.
Opposing View
Although I was asked to present the opposing view regard-
ing the use of adjunctive dexamethasone therapy in the treat-
ment of bacterial meningitis, I am not completely opposed to
the administration of dexamethasone for this infection. In
fact, there is convincing evidence that dexamethasone re-
duces neurological sequelae, especially hearing loss, asso-
ciated with meningitis due to Haemophilus influenzae type b
[7, 9, 11]. This was also the conclusion of three influential
groups that put forth guidelines for treatment of meningitis
[17-19]. Several well-conducted, placebo-controlled, dou-
ble blind studies in which optimal antibiotics were used have
found fewer total neurological sequelae at discharge and at
the time of short-term follow-up in children who received
adjunctive dexamethasone therapy compared with those
who received placebo [7, 9, 11]. However, the majority of
the children in these studies had meningitis due to H. influen-
zae type b; thus, the findings cannot necessarily be applied to
cases where meningitis is caused by S. pneumoniae, Neisseria
meningitidis, or other bacteria.
Since the licensure of the polysaccharide vaccine and the
subsequent licensure of H. influenzae type b protein conju-
gate vaccines, the incidence of H. influenzae type b meningi-
tis has dramatically declined [20]. If we assume that this de-
cline will continue and will also be documented in other
countries, then the type of meningitis for which dexametha-
sone has been shown to be beneficial will be encountered
infrequently.
The etiologies of bacterial meningitis for seven recent ran-
domized studies on the use of adjunctive dexamethasone
therapy in four countries are shown in table 2 [7-9, 11, 15,
21, 22]. The studies were conducted between 1984 and
1992. Although each study had exclusion criteria related to
underlying illness, prior parenteral antibiotics, or initial CSF
findings, the overall distribution of etiologies probably repre-
sents fairly the relative frequencies of the causes of bacterial
Table 2. Distribution of organisms isolated from patients in stud-
ies in which dexamethasone was used in therapy for meningitis.
Variable
No. (%)
isolated
Percent of organisms isolated
if IT influenzae type b
organisms are excluded
Haemophilus influenzae type b 534 (58)
Neisseria meningitidis 146 (16) 38
Streptococcus pneumoniae 107 (11.7) 28
Other organism 11	 (1.2) 2.9
No isolate* 39 (4.3) 10.2
Aseptic meningitis 52 (5.7) 13.5
Excluded (other reasons) 29 (3.2) 7.5
Total no. of organisms
isolated 915 (...)
NOTE. Seven prospective studies were reviewed [7-9, 11, 15, 21, 22].
* Meningitis was due to a virus.
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meningitis in children. H. influenzae type b accounted for
60% of the cases. If these cases are now excluded, N. meningi-
tidis accounted for 38% of the other case, S. pneumoniae ac-
counted for 28% of the cases, and no isolates were recovered
from 10.2% of the patients (table 2). Almost 14% of the chil-
dren who were initially thought to have bacterial meningitis
when enrolled in these studies were later found to have viral
or aseptic meningitis.
I would like to focus on three basic questions regarding the
efficacy and safety of routine adjunctive dexamethasone ther-
apy in children with suspected bacterial meningitis, taking
into consideration the decline in H. influenzae type b menin-
gitis: (1) What is the evidence that adjunctive therapy with
dexamethasone is efficacious for the treatment of S. pneu-
moniae or N. meningitidis meningitis? (2) What effects, if
any, does dexamethasone have on the treatment of meningi-
tis due to S. pneumoniae that is resistant to penicillin or third-
generation cephalosporins? (3) Does dexamethasone have
any adverse effects on children with viral meningitis?
The studies referred to previously did not enroll enough
children with meningitis due to S. pneumoniae or N. meningi-
tidis to establish the efficacy of dexamethasone in treating
cases with these etiologies. Even when the data from selected
studies are combined to obtain some estimate of the efficacy
of dexamethasone for treating pneumococcal meningitis, a
significant difference in outcome for the dexamethasone-
treated children is not seen.
A large, open, prospective study conducted in Egypt [10]
compared therapy that included dexamethasone to that with
no adjunctive measure for children and adults who were
treated for bacterial meningitis with intramuscular ampicillin
and chloramphenicol [10]. The dramatic finding was that the
case-fatality rate for pneumococcal meningitis was reduced
from 40.7% (22 of 54) among the controls to 13.5% (7 of 52)
in the dexamethasone group (P < .002). Furthermore, none
of 45 patients receiving dexamethasone became deaf due to
S. pneumoniae meningitis (P < .05), whereas 4 of 32 in the
control group did; however, hearing could not be evaluated
in children <4 years old. The application of the results from
this Egyptian study to the use of dexamethasone in the treat-
ment of pneumococcal meningitis in the United States is
problematic for the following reasons: the ampicillin dose
was low (160 mg/[kg • d]) when compared with the standard
recommended dose [23]; a high percentage of patients with
pneumococcal meningitis were comatose on admission (79%
in dexamethasone group and 69% in the control group) and
had suboptimal supportive care; and it was not clear if chlor-
amphenicol therapy was discontinued once S. pneumoniae
was identified (prolonged combination therapy with ampicil-
lin and chloramphenicol might be antagonistic for pneumo-
coccal meningitis [24]. It should also be noted that no bene-
fit was found when dexamethasone therapy was used to treat
meningitis due to N. meningitides, the organism most com-
monly isolated in this study.
In a retrospective study, Kennedy et al. [16] reviewed the
records of 97 children with pneumococcal meningitis who
were treated at Parkland Memorial Hospital or Childrens
Medical Center in Dallas between 1984 and 1990. Forty-one
patients received dexamethasone and 56 did not. Although
the ages, duration of illness, and several other clinical fea-
tures were similar between the groups, important differences
were present in other areas. In the dexamethasone group 51%
of children were white, whereas in the group not treated with
dexamethasone, 39% were white. Although this is a not signif-
icant difference, it shows there were differences based on the
racial makeup of the groups. There was a significant differ-
ence (P < .001) in the number of children in the years 1984-
1987 who were not treated with dexamethasone (44 of 56)
compared with the number who were treated with dexameth-
asone (10 of 41) during that period. The main concern is that
the children treated in the earlier years received different
antibiotics (including cefuroxime) than did the children seen
after 1987, at which time cefotaxime or ceftriaxone was ad-
ministered more frequently. This may be an important factor
since there is some evidence that cefuroxime is inferior to
ceftriaxone for treating bacterial meningitis. In one prospec-
tive evaluation, two of six children treated with cefuroxime
vs. none of seven children receiving ceftriaxone for pneumo-
coccal meningitis developed a hearing impairment [25].
Overall, 4 of 35 children who received dexamethasone
compared with 14 of 43 children who did not receive dexa-
methasone had an adverse neurological and/or audiological
outcome (P = .033). A bilateral hearing loss (moderate or
greater) occurred in 3 (9%) of 35 steroid-treated and 10 (21%)
of 47 nonsteroid-treated patients (P = .14). However, if
more children in the nonsteroid group than were in the ste-
roid group were treated with cefuroxime, the interpretation
of these results on hearing loss might be altered.
I believe that these two studies do not provide sufficient
evidence that dexamethasone is beneficial for the treatment
of pneumococcal meningitis. The question then becomes: is
there a disadvantage in administering dexamethasone to
such children? Gastrointestinal bleeding may occur more
commonly in children receiving dexamethasone, but serious
hemorrhaging rarely develops.
A problem of growing concern is the increasing number of
reports of the isolation of S. pneumoniae strains that are resis-
tant to penicillin and/or third-generation cephalosporins. In
many cases, vancomycin is the agent chosen to treat such
infections. How or whether dexamethasone affects the treat-
ment of bacterial meningitis in these patients is unknown.
To date, three of eight patients in whom cefotaxime or cef-
triaxone treatment for pneumococcal meningitis failed had
received adjunctive therapy with dexamethasone [26]. In
other cases, prolonged dexamethasone administration has
been associated with CSF cultures that remain persistently
positive for S. pneumoniae in otherwise healthy children who
have been appropriately treated for meningitis [27]. In the
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study by Kennedy et al. [16], 2 (7%) of 30 dexamethasone-
treated and none of 35 nondexamethasone-treated patients
had a positive CSF culture 24-48 hours after therapy was
begun (P = .21).
Administration of dexamethasone is associated with a
more rapid decrease in fever and could result in an inaccu-
rate clinical appraisal of the patient's response (the clinician
might assume that the child is responding favorably to the
antibiotic administered but defervescence is due to dexa-
methasone therapy). On the other hand, the recurrence of
fever in these patients may alert the physician to a possible
poor response to antibiotic therapy; however, this can also
simply be due to the discontinuation of dexamethasone ther-
apy. An example of this problem is seen in the report by
Viladrich et al. [28] in which vancomycin therapy for pneu-
mococcal meningitis in adults was evaluated. The authors
reported that vancomycin therapy failed in 4 of 11 adults,
and they defined treatment failure as a recrudescence of a
patient's illness based on a rise in temperature and recur-
rence of meningeal signs and symptoms after clear, initial
clinical improvement. However, all patients in that study
had also received dexamethasone for four days, and clinical
relapse had occurred on days 4 (2 patients), 7 ( I patient),
and 8 ( I patient) of therapy; certainly in two of these patients
(those who relapsed on day 7 and 8), dexamethasone therapy
had been discontinued before the fever recurred. Unfortu-
nately, because a suboptimal dose of vancomycin and be-
cause a repeated CSF analysis was not performed, it is not
clear whether treatment truly failed or if the reappearance of
fever and symptoms was related to the inadequate dose or to
the discontinuation of dexamethasone therapy.
Because of the decline in the incidence of H. influenzae
type b meningitis, a greater proportion of patients who will
receive dexamethasone for suspected bacterial meningitis
will be children with viral meningitis. In real-life situations,
children with viral or aseptic meningitis may make up an
even greater proportion of patients treated with dexametha-
sone; the discrepancy in numbers is due to the fact that in-
vestigators involved in the various studies are probably more
selective in considering which children to enroll, whereas a
physician not involved in a study does not have to make such
considerations when encountering a child whose CSF shows
pleocytosis. Many children with viral meningitis initially
have a predominance of polymorphonuclear leukocytes in
the CSF, which may make it difficult to distinguish readily
between viral and bacterial meningitis at the time ofpresenta-
tion. Such children are sometimes given dexamethasone em-
pirically until the etiology of the meningitis is clarified; thus,
we must be certain that dexamethasone will not have adverse
effects on the outcome of aseptic meningitis. The report by
Waggner et al. [29] is the only one that addresses this issue.
They reviewed the clinical course of 32 hospitalized children
with aseptic meningitis who received dexamethasone after
being enrolled in Dallas study protocols. The clinical course
of these children during the hospital stay and condition at
discharge were unusual for children with aseptic meningitis.
After discharge, follow-up conducted by a phone interview
with parents indicated that the children had returned to their
usual activity levels and behavior. No long-term follow-up
examinations were performed, and the records of those chil-
dren with aseptic meningitis who did not receive dexametha-
sone were not reviewed. Certainly, additional studies are re-
quired before we can be certain that dexamethasone therapy
is not detrimental to children with viral meningitis, including
long-term subtle effects on behavior or intellect that may be
seen at follow-up.
I have highlighted my concerns regarding the evidence
that dexamethasone is safe and efficacious for the adjunctive
treatment of bacterial meningitis, taking into consideration
the fact that the one type of meningitis for which it is proven
beneficial (H. influenzae type b) has markedly diminished in
incidence due to the development of remarkable vaccines. It
is hoped that well-designed, prospective studies of adjunctive
dexamethasone therapy for pneumococcal meningitis will be
conducted or that an effective pneumococcal conjugate vac-
cine will be developed, ending this debate.
Comment
There was general agreement among the speakers and the
large audience that the etiology of bacterial meningitis in
infants and children has dramatically changed in countries
where conjugate H. influenzae vaccines are routinely used.
As pointed out by Drs. Schaad and Kaplan, the efficacy of
dexamethasone therapy in humans has only been proven for
H. influenzae meningitis. In several studies of experimental
pneumococcal meningitis, dexamethasone was effective in
modulating meningeal inflammation, including cerebral
edema and intracranial pressure [1,4 In the two clinical
trials of pneumococcal meningitis mentioned previously [ 10,
16], there was evidence suggesting that steroid therapy im-
proved outcome. There is no information on the efficacy of
dexamethasone in treating meningococcal meningitis; be-
cause sequelae occur in <10% of these patients, a very large
number of patients would need to be studied to establish its
efficacy.
At present, physicians must base their decision to use dexa-
methasone therapy in patients with pneumococcal or menin-
gococcal meningitis on the evidence presented and on per-
sonal experience. Additional data are needed to determine
the optimal treatment for meningitis caused by penicillin-re-
sistant and cephalosporin-resistant pneumococci. The effect
of dexamethasone therapy on the activity of the cephalospo-
rins and vancomycin and their penetration into the CSF of
these patients is required before definitive recommendations
can be made. Data derived from studies of experimental
pneumococcal meningitis clearly indicate that dexametha-
sone reduces the CSF penetration of ceftriaxone and vanco-
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mycin sufficiently to alter the clearance of resistant organ-
isms from CSF cultures [30]. Penetration of rifampin into the
CSF appears to be unaffected by concomitant dexametha-
sone therapy.
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